Cargando…
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
BACKGROUND: Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720542/ https://www.ncbi.nlm.nih.gov/pubmed/23841950 http://dx.doi.org/10.1186/1475-2875-12-235 |
_version_ | 1782277957911314432 |
---|---|
author | Staehli Hodel, Eva Maria Guidi, Monia Zanolari, Boris Mercier, Thomas Duong, Socheat Kabanywanyi, Abdunoor M Ariey, Frédéric Buclin, Thierry Beck, Hans-Peter Decosterd, Laurent A Olliaro, Piero Genton, Blaise Csajka, Chantal |
author_facet | Staehli Hodel, Eva Maria Guidi, Monia Zanolari, Boris Mercier, Thomas Duong, Socheat Kabanywanyi, Abdunoor M Ariey, Frédéric Buclin, Thierry Beck, Hans-Peter Decosterd, Laurent A Olliaro, Piero Genton, Blaise Csajka, Chantal |
author_sort | Staehli Hodel, Eva Maria |
collection | PubMed |
description | BACKGROUND: Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability. METHODS: Drug concentrations were measured in 143 patients in Tanzania (artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine), and in 63 (artesunate, dihydroartemisinin and mefloquine) and 60 (dihydroartemisinin and piperaquine) patients in Cambodia. Inter- and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM(®)). RESULTS: A one-compartment model with first-order absorption from the gastrointestinal tract fitted the data for all drugs except piperaquine (two-compartment). Inter-individual variability in concentration exposure was about 40% and 12% for mefloquine. From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs’ pharmacokinetic profiles. Artesunate and dihydroartemisinin could not be studied in the Cambodian patients due to insufficient data-points. Modeled lumefantrine kinetics showed that the target day 7 concentrations may not be achieved in a substantial proportion of patients. CONCLUSION: The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates. Dosing on body weight appears justified. The concomitance of unregulated drug use (residual levels found on admission) and sub-optimal exposure (variability) could generate low plasma levels that contribute to selecting for drug-resistant parasites. |
format | Online Article Text |
id | pubmed-3720542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37205422013-07-26 Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients Staehli Hodel, Eva Maria Guidi, Monia Zanolari, Boris Mercier, Thomas Duong, Socheat Kabanywanyi, Abdunoor M Ariey, Frédéric Buclin, Thierry Beck, Hans-Peter Decosterd, Laurent A Olliaro, Piero Genton, Blaise Csajka, Chantal Malar J Research BACKGROUND: Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability. METHODS: Drug concentrations were measured in 143 patients in Tanzania (artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine), and in 63 (artesunate, dihydroartemisinin and mefloquine) and 60 (dihydroartemisinin and piperaquine) patients in Cambodia. Inter- and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM(®)). RESULTS: A one-compartment model with first-order absorption from the gastrointestinal tract fitted the data for all drugs except piperaquine (two-compartment). Inter-individual variability in concentration exposure was about 40% and 12% for mefloquine. From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs’ pharmacokinetic profiles. Artesunate and dihydroartemisinin could not be studied in the Cambodian patients due to insufficient data-points. Modeled lumefantrine kinetics showed that the target day 7 concentrations may not be achieved in a substantial proportion of patients. CONCLUSION: The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates. Dosing on body weight appears justified. The concomitance of unregulated drug use (residual levels found on admission) and sub-optimal exposure (variability) could generate low plasma levels that contribute to selecting for drug-resistant parasites. BioMed Central 2013-07-10 /pmc/articles/PMC3720542/ /pubmed/23841950 http://dx.doi.org/10.1186/1475-2875-12-235 Text en Copyright © 2013 Staehli Hodel et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Staehli Hodel, Eva Maria Guidi, Monia Zanolari, Boris Mercier, Thomas Duong, Socheat Kabanywanyi, Abdunoor M Ariey, Frédéric Buclin, Thierry Beck, Hans-Peter Decosterd, Laurent A Olliaro, Piero Genton, Blaise Csajka, Chantal Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients |
title | Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients |
title_full | Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients |
title_fullStr | Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients |
title_full_unstemmed | Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients |
title_short | Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients |
title_sort | population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in cambodian and tanzanian malaria patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720542/ https://www.ncbi.nlm.nih.gov/pubmed/23841950 http://dx.doi.org/10.1186/1475-2875-12-235 |
work_keys_str_mv | AT staehlihodelevamaria populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT guidimonia populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT zanolariboris populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT mercierthomas populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT duongsocheat populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT kabanywanyiabdunoorm populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT arieyfrederic populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT buclinthierry populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT beckhanspeter populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT decosterdlaurenta populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT olliaropiero populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT gentonblaise populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients AT csajkachantal populationpharmacokineticsofmefloquinepiperaquineandartemetherlumefantrineincambodianandtanzanianmalariapatients |